



TEXAS DEPARTMENT OF STATE HEALTH SERVICES

DAVID L. LAKEY, M.D.
COMMISSIONER

P.O. Box 149347
Austin, Texas 78714-9347
1-888-963-7111
TTY: 1-800-735-2989
www.dshs.state.tx.us

The Deputy Administrator of the Drug Enforcement Administration (DEA) placed the substances, boldione (androsta-1,4-diene-3,17-dione), desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol; madol), and 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione) into Schedule III of the United States Controlled Substance Act (USCSA) effective January 4, 2010. This final rule was published in the Federal Register, Volume 74, Number 232, pages 63603 - 63610. The Deputy Administrator of the DEA based this action on the following:

- (1) The substance is chemically related to testosterone;
- (2) the substance is pharmacologically related to testosterone;
- (3) the substance is not an estrogen, progestin, or a corticosteroid;
- (4) the substance is not dehydroepiandrosterone (DHEA); and,
- (5) any substance that meets the criteria is considered an anabolic steroid and must be listed as a schedule III controlled substance.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced action was published in the Federal Register; and, in my capacity as Commissioner of the Texas Department of State Health Services, I do hereby order that the substances boldione (androsta-1,4-diene-3,17-dione), desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol; madol), and 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione) be added to Schedule III of the Texas Controlled Substances Act.

SCHEDULE III

Schedule III consists of:

- Schedule III depressants

* * *

- Nalorphine
- Schedule III narcotics

* * *

- Schedule III stimulants

* * *

- Schedule III anabolic steroids and hormones

Anabolic steroids, including any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and include the following:

(1) androstenediol

(1-1) 3 beta,17 beta-dihydroxy-5 alpha-androstane;

(1-2) 3 alpha,17 beta -dihydroxy-5 alpha-androstane;

(2) androstenedione (5 alpha-androstan-3,17-dione);

(3) androstenediol--

(3-1) 1-androstenediol (3 beta,17 beta-dihydroxy-5 alpha-androst-1-ene);

(3-2) 1-androstenediol (3 alpha,17 beta-dihydroxy-5 alpha-androst-1-ene);

(3-3) 4-androstenediol (3 beta,17 beta-dihydroxy-androst-4-ene);

(3-4) 5-androstenediol (3 beta,17 beta-dihydroxy-androst-5-ene);

(4) androstenedione--

(4-1) 1-androstenedione ([5 alpha]-androst-1-en-3,17-dione);

(4-2) 4-androstenedione (androst-4-en-3,17-dione);

(4-3) 5-androstenedione (androst-5-en-3,17-dione);

(5) bolasterone (7 alpha,17 alpha-dimethyl-17 beta-hydroxyandrost-4-en-3-one);

(6) boldenone (17 beta-hydroxyandrost-1,4,-diene-3-one);

*(7) boldione (androsta-1,4-diene-3,17-dione)

(8) calusterone (7 beta,17 alpha-dimethyl-17 beta-hydroxyandrost-4-en-3-one);

(9) clostebol (4-chloro-17 beta-hydroxyandrost-4-en-3-one);

- (10) dehydrochloromethyltestosterone (4-chloro-17 beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);
- (11) delta-1-dihydrotestosterone (a.k.a. `1-testosterone') (17 beta-hydroxy-5 alpha-androst-1-en-3-one);
- * (12) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol; madol)
- (13) 4-dihydrotestosterone (17 beta-hydroxy-androstan-3-one);
- (14) drostanolone (17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one);
- (15) ethylestrenol (17 alpha-ethyl-17 beta-hydroxyestr-4-ene);
- (16) fluoxymesterone (9-fluoro-17 alpha-methyl-11 beta,17 beta-dihydroxyandrost-4-en-3-one);
- (17) formebolone (2-formyl-17 alpha-methyl-11 alpha,17 beta-dihydroxyandrost-1,4-dien-3-one);
- (18) furazabol (17 alpha-methyl-17 beta-hydroxyandrostano[2,3-c]-furazan);
- (19) 13 beta-ethyl-17 beta-hydroxygon-4-en-3-one;
- (20) 4-hydroxytestosterone (4,17 beta-dihydroxy-androst-4-en-3-one);
- (21) 4-hydroxy-19-nortestosterone (4,17 beta-dihydroxy-estr-4-en-3-one);
- (22) mestanolone (17 alpha-methyl-17 beta-hydroxy-5 alpha-androstan-3-one);
- (23) mesterolone (1 alpha-methyl-17 beta-hydroxy-[5 alpha]-androstan-3-one);
- (24) methandienone (17 alpha-methyl-17 beta-hydroxyandrost-1,4-dien-3-one);
- (25) methandriol (17 alpha-methyl-3 beta,17 beta-dihydroxyandrost-5-ene);
- (26) methenolone (1-methyl-17 beta-hydroxy-5 alpha-androst-1-en-3-one);
- (27) 17 alpha-methyl-3 beta, 17 beta-dihydroxy-5 alpha-androstane;
- (28) 17alpha-methyl-3 alpha,17 beta-dihydroxy-5 alpha-androstane;
- (29) 17 alpha-methyl-3 beta,17 beta-dihydroxyandrost-4-ene;
- (30) 17 alpha-methyl-4-hydroxynandrolone (17 alpha-methyl-4-hydroxy-17 beta-hydroxyestr-4-en-3-one);
- (31) methyldienolone (17 alpha-methyl-17 beta-hydroxyestra-4,9(10)-dien-3-one);
- (32) methyltrienolone (17 alpha-methyl-17 beta-hydroxyestra-4,9-11-trien-3-one);
- (33) methyltestosterone (17 alpha-methyl-17 beta-hydroxyandrost-4-en-3-one);
- (34) mibolerone (7 alpha,17 alpha-dimethyl-17 beta-hydroxyestr-4-en-3-one);
- (35) 17 alpha-methyl-delta-1-dihydrotestosterone (17 beta-hydroxy-17 alpha-methyl-5 alpha-androst-1-en-3-one) (a.k.a. `17-alpha-methyl-1-testosterone');
- (36) nandrolone (17 beta-hydroxyestr-4-en-3-one);
- (37) norandrostenediol--
- (37-1) 19-nor-4-androstenediol (3 beta, 17 beta-dihydroxyestr-4-ene);
- (37-2) 19-nor-4-androstenediol (3 alpha, 17 beta-dihydroxyestr-4-ene);
- (37-3) 19-nor-5-androstenediol (3 beta, 17 beta-dihydroxyestr-5-ene);


- (37-4) 19-nor-5-androstenediol (3 alpha, 17 beta-dihydroxyestr-5-ene);
- (38) norandrostenedione—
- (38-1) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- (38-2) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- *(39) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)
- (40) norbolethone (13 beta,17alpha-diethyl-17 beta-hydroxygon-4-en-3-one);
- (41) norclostebol (4-chloro-17 beta-hydroxyestr-4-en-3-one);
- (42) norethandrolone (17 alpha-ethyl-17 beta-hydroxyestr-4-en-3-one);
- (43) normethandrolone (17 alpha-methyl-17 beta-hydroxyestr-4-en-3-one);
- (44) oxandrolone (17 alpha-methyl-17 beta-hydroxy-2-oxa-[5 alpha]-androstan-3-one);
- (45) oxymesterone (17 alpha-methyl-4,17 beta-dihydroxyandrost-4-en-3-one);
- (46) oxymetholone (17 alpha-methyl-2-hydroxymethylene-17 beta-hydroxy-[5 alpha]-androstan-3-one);
- (47) stanozolol (17 alpha-methyl-17 beta-hydroxy-[5 alpha]-androst-2-eno[3,2-c]-pyrazole);
- (48) stenbolone (17 beta-hydroxy-2-methyl-[5 alpha]-androst-1-en-3-one);
- (49) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
- (50) testosterone (17 beta-hydroxyandrost-4-en-3-one);
- (51) tetrahydrogestrinone (13 beta,17 alpha-diethyl-17 beta-hydroxygon-4,9,11-trien-3-one);
- (52) trenbolone (17 beta-hydroxyestr-4,9,11-trien-3-one); and
- (53) any salt, ester, or ether of a drug or substance described in this paragraph.

- Schedule III hallucinogenic substances

* * *

Changes to the Schedules are designated by an asterisk (*)

Done in Austin, Texas this 13th day of March, 2010 in witness whereof I hereunto set my hand and seal of office.



David L. Lakey, M.D.
Commissioner